Company Profile

NovoBiotic Pharmaceuticals LLC
Profile last edited on: 11/5/2019      CAGE: 48R19      UEI: GUV4CZLZE5Z2

Business Identifier: Antibiotics from microorganisms: new drugs from natural sources
Year Founded
First Award
Latest Award
Program Status
Popularity Index
Is this YOUR Company?
Ensure accuracy and completeness of YOUR Company Profile by completing the brief Survey Instrument attached
Do you know about this Awardees?
Let us encourage you to provide any data which would enhance the completeness of this firm's profile.

Location Information

767C Concord Avenue
Cambridge, MA 02138
   (617) 864-2880
Location: Single
Congr. District: 05
County: Middlesex

Public Profile

NovoBiotic Pharmaceuticals is a biotechnology company focused on discovery and development of new drugs from natural sources with a particular focus on the discovery of new antibiotics targeting serious drug-resistant infections. While many marketed antibiotics are derived from microbes found in the soil, few new classes have been introduced in more that 50 years. Big pharma have exhaustively screened the readily culturable microbes, which represent <1% of microbes in the environment but the vast majority of microbes in nature have remained uncultured and inaccessible to drug discovery. NovoBiotic has discovered a unique, proprietary method to isolate and cultivate previously unculturable microorganisms in the laboratory, giving NovoBiotic sole access to a virtually unlimited and as yet unexploited source of novel natural product compound diversity. This unique access to natural product diversity represents one of the most valuable assets for modern drug discovery. With the focus on identifying new antibiotics from these novel sources, longer term the company will leverage the value of this unique, microbe-derived chemical diversity in therapeutic areas such as oncology, atherosclerosis, and inflammatory diseases.

Extent of SBIR involvement

User Avatar

Synopsis: Awardee Business Condition

Employee Range
Revenue Range
VC funded?
Privately Held
Stock Info
IP Holdings

Awards Distribution by Agency

Most Recent SBIR Projects

Year Phase Agency Total Amount
2023 2 NIH $1,996,273
Project Title: Teixobactin Development for Tuberculosis
2021 2 NIH $3,196,288
Project Title: Preclinical Development of Novo29; a New Antibiotic
2021 2 NIH $596,026
Project Title: Antibiotic discovery from a new genus of uncultured bacteria.
2021 2 NIH $2,989,151
Project Title: Teixobactin Development for Anthrax
2020 2 NIH $4,468,251
Project Title: Preclinical Development of Teixobactin, a New Antibiotic

Key People / Management

  Dallas E Hughes -- President

  Aram Salzman -- former President

  Slava Epstein -- Co-founder

  Kim Lewis -- Co-founder

  Losee L Ling -- VP of Biology

  Charles Michael Moore

  Aaron Peoples -- Director of Chemistry

  Amy L Spoering -- Director of Biological Research

  Andrew L Staley